SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study.
Martin T, Strickland S, Glenn M et al.
Key Points:
SAR650984(SAR) monoclonal antibody binds to human CD38 antigen highly expressed in multiple myeloma cells.
32 patients who progressed after first line of treatment selected for trial (3 patients with NHL, 2 with CLL, and 27 with MM).
Adverse events: grade 3 pneumonia (6.3%), fever (3.1%), hyperglycemia (3.1%), grade 2 infusion reaction (3.1%).
Implications:
MTD not reached in study.
SAR demonstrates encouraging single agent activity.
View the original abstract on the ASH website.
